ClinicalTrials.gg
TerminatedNCT04032847Updated Mar 10, 2025Results posted

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

A Phase 1/2 interventional study of ATL001 and Pembrolizumab in Advanced Non Small Cell Lung Cancer, sponsored by Achilles Therapeutics UK Limited. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Achilles Therapeutics UK Limited · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom — 102 open to participants now, 201 under way, 94 of them phase 3. Carcinoma, Non-Small-Cell Lung · United Kingdom.

Enrollment
482nd of 520
27 · median 272
Started
2019
with 30 others
Phase 1/2
70 of 568
21 open now
Registered
331st of 568
by date

Among the 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, this one is the 482nd largest by enrollment of the 520 interventional ones that give a count, is one of 31 that started in 2019, is one of 70 in phase 1/2, and was the 331st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

102 of the 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 568 studies in Carcinoma, Non-Small-Cell Lung with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).

Read the detailed description

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity of autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).

Patients will initially enter the study for procurement of tumour materials required to manufacture ATL001.

Following manufacture of ATL001, the product will be given back to eligible patients following lymphodepletion. Patients will continue to be followed up for a minimum of 5 years, as part of a separate Long Term Follow Up Protocol, or, if the separate protocol is not available at the study site, within this protocol.

03

Conditions studied

  • Advanced Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be at 18-75 years old.
  2. Patients must have confirmed diagnosis of non-small cell lung cancer that is considered to be smoking related.
  3. Patient is considered medically fit to undergo procurement of starting material and ATL001 administration procedures.
  4. Performance Status 0-1.
  5. Adequate organ function per the laboratory parameters defined in the protocol.
  6. Anticipated ≥ 6 months at the time of tissue procurement.
  7. according to 1.1 criteria.

Additional Inclusion Criteria will apply as per the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with untreated, symptomatic or progressing . Lesions should be clinically and radiologically stable for 2 months after treatment and should not require .
  2. Patients with or C, infection (HIV1/2), syphilis or HTLVI/II infection.
  3. Patients for whom there is documented evidence of an actionable tumour driver oncogene mutation (EGFR, ALK or ROS-1) at the time of initial screening. Patients who have progressed on standard targeted therapies, or for whom no approved targeted treatments are available, are not excluded.
  4. Patients requiring treatments.
  5. Patients requiring regular steroids at dose higher than prednisolone 10mg/day (or equivalent)
  6. Patients with superior vena cava syndrome.
  7. Patients with , progressive, and/or uncontrolled renal, hepatic, haematological, endocrine, pulmonary, cardiac, gastroenterological or neurological disease.
  8. Patients with a history of immune mediated central nervous system toxicity, or a history of ≥ Grade 2 diarrhoea/colitis within the past 6 months caused by previous immunotherapy.
  9. Patients with an active concurrent cancer or a history of cancer within the past 3 years (except for in situ carcinomas, early prostate cancer with normal Prostate- Specific Antigen (PSA) or non-melanomatous skin cancers)
  10. Patients with a history of organ transplantation
  11. Patients who have previously received any cell or gene therapies

Additional Exclusion Criteria will apply as per the protocol.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort A

    Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.

    Biological: ATL001

  • Experimental
    Cohort B

    Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL- 2.

    Biological: ATL001 · Drug: Pembrolizumab

  • Experimental
    Cohort C

    Following lymphodepletion with enhanced host conditioning, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.

    Biological: ATL001

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of Treatment Emergent Adverse Events (TEAEs) to Evaluate Safety and Tolerability

    Evaluate TEAEs and serious AEs, by incidence, severity and relationship to ATL001

    Time frame: 62 months due to early termination

Secondary outcomes

  1. Disease Assessment for Change From Baseline in Tumour Size

    Evaluate the clinical activity of ATL001 in patients with advanced NSCLC using change from baseline in tumour size at week 6 , week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR)

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  2. Disease Assessment for Time to Response (TTR) From ATL001 Infusion

    Evaluate the endpoint of TTR by the investigator and ICR, per RECIST v1.1 and im-RECIST

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  3. Disease Assessment for Objective Response Rate (ORR)

    Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.

    Time frame: Every 6 weeks for 6 months, then every 3 months (up to 62 months due to early termination)

  4. Disease Assessment for Duration of Response (DoR). The DoR is Defined as the Time From the Date of First Documented Response Until the Date of Documented Disease Progression or Death

    Evaluate the endpoint of DOR by the investigator and ICR, per RECIST v1.1 and im-RECIST

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  5. Disease Assessment for Disease Control Rate (DCR)

    Evaluate the endpoints of DCR as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  6. Disease Assessment for Progression-Free Survival (PFS)

    Evaluate the efficacy endpoints of PFS as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  7. Overall Survival (OS)

    Evaluate OS by the investigator

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

07

Results

Posted Mar 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort BCohort C
Started2205
Completed000
Not completed2205
Withdrew: Study termination by sponsor804
Withdrew: Death1200
Withdrew: Progressive disease201

Outcome measures

PrimaryAssessment of Treatment Emergent Adverse Events (TEAEs) to Evaluate Safety and Tolerability

Evaluate TEAEs and serious AEs, by incidence, severity and relationship to ATL001

Time frame:
62 months due to early termination
Reported as:
Count of participants · Participants
Assessment of Treatment Emergent Adverse Events (TEAEs) to Evaluate Safety and Tolerability
ParticipantsCohort ACohort BCohort C
TEAEs21—5
TEAEs related to any component of study treatment19—5
Lymphodepletion related TEAEs16—4
ATL001 related TEAEs16—4
IL-2 related TEAEs16—5
Serious TEAEs6—0
Serious TEAEs related to any component of study treatment2—0
Serious Lymphodepletion related TEAEs1—0
Serious ATL001 related TEAEs1—0
Serious IL-2 related TEAEs0—0
TEAEs with CTCAE grade >= 316—5
TEAEs with CTCAE grade >= 3 related to any component of study treatment14—4
Lymphodepletion related TEAEs with CTCAE grade >= 312—4
ATL001 related TEAEs with CTCAE grade >= 34—2
IL-2 related TEAEs with CTCAE grade >= 36—3
TEAEs leading to death0—0
SAEs800
SecondaryDisease Assessment for Change From Baseline in Tumour Size

Evaluate the clinical activity of ATL001 in patients with advanced NSCLC using change from baseline in tumour size at week 6 , week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR)

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Time to Response (TTR) From ATL001 Infusion

Evaluate the endpoint of TTR by the investigator and ICR, per RECIST v1.1 and im-RECIST

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Objective Response Rate (ORR)

Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.

Time frame:
Every 6 weeks for 6 months, then every 3 months (up to 62 months due to early termination)
Reported as:
Count of participants · Participants
Disease Assessment for Objective Response Rate (ORR)
ParticipantsCohort ACohort BCohort C
Responders200
Non-Responders2005
SecondaryDisease Assessment for Duration of Response (DoR). The DoR is Defined as the Time From the Date of First Documented Response Until the Date of Documented Disease Progression or Death

Evaluate the endpoint of DOR by the investigator and ICR, per RECIST v1.1 and im-RECIST

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Disease Control Rate (DCR)

Evaluate the endpoints of DCR as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Progression-Free Survival (PFS)

Evaluate the efficacy endpoints of PFS as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Evaluate OS by the investigator

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

Adverse events

Collected over Each patient that received ATL001 would have been followed up for 24 months, to withdrawal of consent or death. Patients would then continue to be followed up for a minimum of 5 years as part of long term follow up. The study was terminated early due to sponsor decision. The Median follow-up period was 12 weeks (range: 3 - 48 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A14/22 (63.6%)8/22 (36.4%)22/22 (100%)
Cohort C1/5 (20%)0/5 (0%)5/5 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventCohort ACohort C
PneumothoraxRespiratory, thoracic and mediastinal disorders2/220/5
Febrile neutropeniaBlood and lymphatic system disorders1/220/5
DyspnoeaRespiratory, thoracic and mediastinal disorders1/220/5
Subcutaneous emphysemaSkin and subcutaneous tissue disorders1/220/5
AscitesGastrointestinal disorders1/220/5
TachypnoeaRespiratory, thoracic and mediastinal disorders1/220/5
ConstipationGastrointestinal disorders1/220/5
EncephalopathyNervous system disorders1/220/5
VomitingGastrointestinal disorders1/220/5
Confusional statePsychiatric disorders1/220/5
Most frequent other events
Showing 10 of 66
Most frequent other events
EventCohort ACohort C
AnaemiaBlood and lymphatic system disorders14/224/5
Lymphocyte count decreasedInvestigations4/224/5
Platelet count decreasedInvestigations0/224/5
NauseaGastrointestinal disorders15/223/5
Neutrophil count decreasedInvestigations5/223/5
DiarrhoeaGastrointestinal disorders8/223/5
RashSkin and subcutaneous tissue disorders3/223/5
InsomniaPsychiatric disorders3/223/5
PyrexiaGeneral disorders13/222/5
FatigueGeneral disorders11/222/5

Baseline characteristics

Cohort B never opened

Age, Customized
Age, Customized(Participants)Cohort ACohort BCohort CTotal
Age — <65 years19—120
Age — >=65 years3—47
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female10—111
Male12—416
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0—00
Asian1—12
Native Hawaiian or Other Pacific Islander0—00
Black or African American0—00
White18—422
More than one race0—00
Unknown or Not Reported3—03
Region of Enrollment
Region of Enrollment(participants)Cohort ACohort BCohort CTotal
United States3—14
United Kingdom11—112
France3—03
Germany4—26
Spain1—12
Body mass index (kg/m^2)
Body mass index (kg/m^2)((kg/m^2))Cohort ACohort BCohort CTotal
Mean26.75 ± 5.818—27.10 ± 4.25626.81 ± 5.490
Baseline ECOG performance status
Baseline ECOG performance status(Participants)Cohort ACohort BCohort CTotal
Grade 08—210
Grade 114—317
08

Study locations

19 sites
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10017, United States
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69310, France
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Hospital Clinic de Barcelona
    Barcelona, Catalonia 08036, Spain
  • Instituto de Investigación Sanitaria Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Centro Integral Oncologico Clara Campal Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital
    Cambridge, United Kingdom
  • The Leeds Teaching Hospitals NHS Trust, St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • University College London Hospitals (UCLH) NHS Foundation Trust, University College Hospital
    London, NW1 2PG, United Kingdom
  • Guys and St Thomas' NHS Foundation Trust, Guy's Hospital
    London, SE19RT, United Kingdom
  • The Christie NHS Foundation Trust, Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Manchester University NHS Foundation Trust, Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital
    Newcastle Upon Tyne, United Kingdom
  • University Hospital Southampton NHS Foundation Trust, Southampton General Hospital
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2024, 62 months.

Results were first posted in Mar 2025, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 25, 2019
StartActual
Jul 8, 2019
Primary completionActual
Sep 26, 2024
CompletionActual
Sep 26, 2024
Results first posted
Mar 10, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04032847
Lead sponsor
Achilles Therapeutics UK Limited
Responsible party
Sponsor
First posted
Jul 25, 2019
Start date
Jul 8, 2019
Primary completion
Sep 26, 2024
Completion
Sep 26, 2024
Results posted
Mar 10, 2025
Last update
Mar 10, 2025

Study contacts

Medical Monitor, MD
study director · Achilles Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Clonal Neoantigen T Cells ATL001

Start the discussion